Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Date:1/31/2008

tual results to differ materially from those in the forward-

looking statements. Such risks and uncertainties include, among others,

the availability of funds and resources to pursue research and

development projects, the efficacy of REOLYSIN(R) as a cancer treatment,

the tolerability of REOLYSIN(R) outside a controlled test, the success

and timely completion of clinical studies and trials, the Company's

ability to successfully commercialize REOLYSIN(R), uncertainties related

to the research and development of pharmaceuticals and uncertainties

related to the regulatory process. Investors should consult the Company's

quarterly and annual filings with the Canadian and U.S. securities

commissions for additional information on risks and uncertainties

relating to the forward-looking statements. Investors are cautioned

against placing undue reliance on forward-looking statements. The Company

does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Global Stem Cells Group has announced ... April 27 - 29, 2015 in Boston. This world-class ... of stem cell research including applications, biology, medicine, regulations, ... , The conference will address recent developments in ... in stem cell therapies, regenerative medicine, tissue engineering, stem ...
(Date:4/16/2015)... Spirax Sarco, the leader in ... newly designed, state-of-the-art website in the first quarter ... promotes the Spirax Sarco brand, company capabilities, and ... a site visitor might be looking for including ... serviced, the latest company news, careers, and much ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, ... technology, has signed a long-term lease on Laboratory Drive ... North Carolina . The location will house review ... to provide high quality reviews and customer service to ... represented Schulman in the deal, while Capital ...
Breaking Biology Technology:Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that ... on the progress of Sangamo,s ZFP Therapeutic(TM) development programs and ... ET on Tuesday, November 10, 2009 at the Merriman Curhan ... New York City. , The presentation will be webcast live ...
... ... therapy has created an international medical first and raised the hope of patients with pulmonary fibrosis, ... ... adult stem cell therapy has created an international medical first and raised the hope ...
... has won a $4.4 million grant from the ... (ARPA-E) to lead a multidisciplinary, multi-institutional research project ... magnets. Stronger magnets are essential for increasing ... and communications systems in the 21st-century, and for ...
Cached Biology Technology:Sangamo BioSciences Announces Presentation at Merriman Curhan Ford's Investor Summit 2009 2Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 2Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 3UD wins $4.4 million to develop next-generation magnets 2
(Date:4/1/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces the second shipment of ... to early access pre-order customers. Feedback ... outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop & ... at all outlets and very easy to use. Several ...
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... crickets adapt to rising temperatures may provide clues about ... UCF scientist Wade Winterhalter landed an $860,000 grant from ... that fuses global warming models with a biological model ... cricket, also known as the Allonemobius socius. If ...
... gather 12-13 March for the 58th annual meeting of ... The meeting takes place at the Hilton St. Petersburg ... the University of South Florida (USF) Department of Geology ... Alumni Society. Journalists are invited to attend sessions ...
... A handful of proteins, detected in incredibly tiny amounts, ... lesion in the pancreas and a potentially deadly one, ... The researchers believe that these protein biomarkers, if ... pancreatic cancer or precancerous pancreatic lesions, which would allow ...
Cached Biology News:Crickets may predict human survivability during global warming 2Tiny samples could yield big predictive markers for pancreatic cancer 2Tiny samples could yield big predictive markers for pancreatic cancer 3
Limit of detection: <5 pg/ml...
Image Analysis Software. PC Version of NIH Image....
FITC~Bovine Serum Albumin...
Bovine Serum Albumin Heat Shock Diagnostic Grade Powder...
Biology Products: